• Half-Year Review of Inventiva’s Liquidity Contract with Kepler Cheuvreux

    Source: Nasdaq GlobeNewswire / 21 Jul 2022 12:00:00   America/New_York

    Daix (France), Long Island City (New York, United States), July 21, 2022 – Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of NASH and other diseases with significant unmet medical needs, today announced the half-year report of its liquidity contract with Kepler Cheuvreux.

    Under the liquidity contract granted to Kepler Cheuvreux by Inventiva, the following resources were available in the liquidity account as of June 30, 2021:

    • Cash: € 316,759.75
    • Number of shares: 100,139
    • Number of executions on buy side on semester: 993
    • Number of executions on sell side on semester: 636
    • Traded volume on buy side on semester: 152,845 shares for € 1,470,441.72
    • Traded volume on sell side on semester: 98,168 shares for € 1,025,659.18

    At the last half-year report as of December 31, 2021, the following resources were available in the liquidity account:

    • Cash: € 761,542.29
    • Number of shares: 45,462
    • Number of executions on buy side on semester: 1,253
    • Number of executions on sell side on semester: 1,425
    • Traded volume on buy side on semester: 209,935 shares for € 2,438,368.87
    • Traded volume on sell side on semester: 211,076 shares for € 2,510,782.11

    When the contract was initially implemented, the following resources were included in the liquidity account:

    • Cash: € 163,510.42
    • Number of shares: 34,063

     

      Buy Side   Sell Side
      Number of
    executions         		Number of
    shares         		Traded volume in EUR   Number of
    executions         		Number of
    shares         		Traded volume in EUR
    Total 993 152,845 1,470,441.72   636 98,168 1,025,659.18
    03/01/2022 8 1,000 11,800.00   12 2,471 29,553.16
    04/01/2022 33 4,501 53,336.85   11 2,000 24,160.00
    05/01/2022 20 1,950 22,542.00   2 500 5,850.00
    06/01/2022 3 49 563.50   - - -
    07/01/2022 38 3,187 36,013.10   - - -
    10/01/2022 30 3,999 43,709.07   - - -
    11/01/2022 7 1,000 10,680.00   13 2,060 22,309.80
    12/01/2022 12 2,000 22,160.00   9 3,440 38,872.00
    13/01/2022 9 500 5,480.00   - - -
    14/01/2022 5 1,500 16,380.00   21 1,614 17,931.54
    17/01/2022 2 1,000 10,980.00   7 639 7,099.29
    19/01/2022 3 222 2,442.00   - - -
    20/01/2022 1 1 11.20   19 3,008 33,689.60
    21/01/2022 8 1,234 13,771.44   6 203 2,285.78
    24/01/2022 30 5,265 57,072.60   - - -
    25/01/2022 1 1 10.54   - - -
    26/01/2022 - - -   8 1,500 16,125.00
    27/01/2022 3 1,000 10,680.00   5 500 5,400.00
    28/01/2022 8 1,319 14,179.25   17 2,537 27,627.93
    31/01/2022 15 1,932 20,614.44   9 2,000 21,560.00
    01/02/2022 - - -   31 5,500 61,105.00
    02/02/2022 - - -   8 1,000 11,800.00
    03/02/2022 10 2,000 22,720.00   11 827 9,436.07
    04/02/2022 4 501 5,691.36   24 1,565 17,966.20
    07/02/2022 3 500 5,750.00   9 2,000 23,340.00
    08/02/2022 3 501 5,811.60   17 3,000 35,580.00
    09/02/2022 7 1,501 17,666.77   16 1,500 17,880.00
    10/02/2022 - - -   1 50 598.00
    11/02/2022 8 542 6,449.80   4 950 11,381.00
    14/02/2022 27 4,852 56,380.24   - - -
    15/02/2022 4 500 5,530.00   - - -
    16/02/2022 4 500 5,550.00   3 501 5,641.26
    17/02/2022 25 2,501 27,511.00   1 422 4,709.52
    18/02/2022 4 1,000 10,860.00   12 2,185 23,947.60
    21/02/2022 31 3,546 38,119.50   - - -
    22/02/2022 23 3,648 37,428.48   5 755 7,776.50
    23/02/2022 - - -   40 4,245 44,827.20
    24/02/2022 31 5,306 53,272.24   2 155 1,612.00
      Buy Side   Sell Side  
      Number of
    executions         		Number of
    shares         		Traded volume in EUR   Number of
    executions         		Number of
    shares         		Traded volume in EUR  
    Total 993 152,845 1,470,441.72   636 98,168 1,025,659.18  
    25/02/2022 - - -   36 4,345 45,622.50  
    28/02/2022 4 500 5,250.00   7 3,500 38,360.00  
    01/03/2022 6 1,749 19,169.04   10 2,109 23,768.43  
    02/03/2022 16 2,548 27,696.76   - - -  
    03/03/2022 11 1,842 19,506.78   - - -  
    04/03/2022 16 2,058 21,403.20   - - -  
    07/03/2022 27 5,430 52,671.00   10 2,500 24,750.00  
    08/03/2022 5 1,501 14,964.97   8 2,501 25,760.30  
    09/03/2022 6 1,000 9,950.00   2 548 5,540.28  
    10/03/2022 - - -   3 500 5,050.00  
    11/03/2022 6 1,000 9,950.00   - - -  
    14/03/2022 4 1,500 15,060.00   6 500 5,050.00  
    15/03/2022 17 2,500 24,575.00   1 23 227.70  
    16/03/2022 6 500 5,000.00   11 1,977 19,849.08  
    17/03/2022 8 1,000 10,100.00   7 1,452 14,955.60  
    18/03/2022 4 500 5,050.00   1 94 958.80  
    21/03/2022 4 1,000 10,000.00   2 407 4,192.10  
    22/03/2022 5 251 2,530.08   14 1,999 20,409.79  
    23/03/2022 3 500 5,150.00   2 500 5,200.00  
    24/03/2022 6 500 5,100.00   - - -  
    25/03/2022 12 926 9,454.46   2 260 2,678.00  
    28/03/2022 4 500 5,095.00   4 548 5,638.92  
    29/03/2022 2 501 5,110.20   14 2,457 25,307.10  
    30/03/2022 3 311 3,234.40   3 495 5,148.00  
    31/03/2022 11 542 5,631.38   - - -  
    01/04/2022 8 1,234 12,685.52   - - -  
    04/04/2022 5 598 6,099.60   6 1,000 10,320.00  
    05/04/2022 1 228 2,325.60   2 500 5,150.00  
    06/04/2022 1 137 1,397.40   1 6 61.80  
    07/04/2022 3 500 5,100.00   3 170 1,751.00  
    08/04/2022 5 473 4,777.30   2 2 20.40  
    11/04/2022 1 485 4,898.50   8 998 10,179.60  
    12/04/2022 10 1,000 10,150.00   3 867 8,886.75  
    13/04/2022 17 1,599 15,910.05   - - -  
    14/04/2022 17 1,500 14,655.00   1 100 990.00  
    19/04/2022 - - -   2 500 4,900.00  
    20/04/2022 1 1 9.70   20 1,500 14,850.00  
    21/04/2022 2 6 59.28   6 500 5,000.00  
      Buy Side   Sell Side  
      Number of
    executions         		Number of
    shares         		Traded volume in EUR   Number of
    executions         		Number of
    shares         		Traded volume in EUR  
    Total 993 152,845 1,470,441.72   636 98,168 1,025,659.18  
    22/04/2022 5 495 4,900.50   - - -  
    25/04/2022 20 1,782 17,231.94   1 7 69.30  
    26/04/2022 11 2,401 22,425.34   - - -  
    27/04/2022 6 2,005 17,984.85   - - -  
    28/04/2022 1 20 180.00   8 1,250 11,400.00  
    29/04/2022 - - -   7 2,000 18,500.00  
    02/05/2022 4 500 4,600.00   11 550 5,120.50  
    03/05/2022 3 150 1,392.00   - - -  
    05/05/2022 2 102 938.40   1 450 4,230.00  
    06/05/2022 6 898 8,315.48   - - -  
    09/05/2022 14 1,980 17,919.00   - - -  
    11/05/2022 10 2,544 22,387.20   9 1,316 11,962.44  
    12/05/2022 10 1,207 10,452.62   - - -  
    13/05/2022 6 678 5,810.46   2 802 7,009.48  
    16/05/2022 8 1,291 10,973.50   - - -  
    17/05/2022 4 1,012 8,551.40   7 1,500 12,900.00  
    18/05/2022 - - -   9 1,131 10,031.97  
    19/05/2022 - - -   5 619 5,614.33  
    20/05/2022 2 251 2,233.90   3 500 4,500.00  
    23/05/2022 3 1,499 13,341.10   4 250 2,262.50  
    24/05/2022 4 275 2,420.00   1 500 4,450.00  
    25/05/2022 - - -   2 400 3,560.00  
    26/05/2022 1 500 4,450.00   3 500 4,500.00  
    27/05/2022 16 2,488 21,645.60   - - -  
    30/05/2022 3 1,000 8,550.00   1 1 8.80  
    31/05/2022 7 750 6,435.00   3 849 7,386.30  
    01/06/2022 - - -   4 500 4,300.00  
    02/06/2022 9 500 4,300.00   2 152 1,322.40  
    03/06/2022 15 1,200 10,224.00   2 149 1,296.30  
    06/06/2022 3 600 5,100.00   1 1 8.60  
    07/06/2022 1 1 8.51   3 189 1,625.40  
    08/06/2022 4 150 1,282.50   4 411 3,538.71  
    09/06/2022 3 655 5,619.90   - - -  
    10/06/2022 8 845 7,233.20   3 500 4,350.00  
    13/06/2022 21 2,488 20,501.12   - - -  
    14/06/2022 21 4,100 32,267.00   - - -  
    15/06/2022 5 1,500 11,220.00   - - -  
    16/06/2022 10 3,000 21,540.00   - - -  
      Buy Side   Sell Side  
      Number of
    executions         		Number of
    shares         		Traded volume in EUR   Number of
    executions         		Number of
    shares         		Traded volume in EUR  
    Total 993 152,845 1,470,441.72   636 98,168 1,025,659.18  
    17/06/2022 3 1,000 7,000.00   1 500 3,600.00  
    20/06/2022 7 1,000 7,000.00   3 971 6,942.65  
    21/06/2022 1 500 3,550.00   3 180 1,299.60  
    22/06/2022 16 4,500 30,375.00   1 500 3,500.00  
    23/06/2022 8 1,000 6,650.00   - - -  
    24/06/2022 - - -   5 500 3,350.00  
    27/06/2022 10 2,000 12,960.00   4 500 3,400.00  
    28/06/2022 7 2,500 15,325.00   1 1 6.50  
    29/06/2022 18 6,000 34,260.00   1 500 2,950.00  
    30/06/2022 - - -   1 4 22.80  
                   

    About Inventiva

    Inventiva is a clinical-stage biopharmaceutical company focused on the research and development of oral small molecule therapies for the treatment of NASH and other diseases with significant unmet medical need. The Company benefits from a strong expertise and experience in the domain of compounds targeting nuclear receptors, transcription factors and epigenetic modulation. Inventiva’s lead product candidate, lanifibranor, is currently in a pivotal Phase III clinical trial, NATiV3, for the treatment of adult patients with NASH, a common and progressive chronic liver disease for which there are currently no approved therapies.

    The Company has established a strategic collaboration with AbbVie in the area of autoimmune diseases that resulted in the discovery of the drug candidate cedirogant (ABBV-157), an oral RORγ inverse agonist which is being evaluated in a Phase IIb clinical trial, led by AbbVie, in adult patients with moderate to severe chronic plaque psoriasis. Inventiva’s pipeline also includes odiparcil, a drug candidate for the treatment of adult mucopolysaccharidoses (MPS) VI patients. As part of Inventiva’s decision to focus clinical efforts on the development of lanifibranor, it suspended clinical efforts relating to odiparcil and is reviewing available options with respect to its potential further development. Inventiva is in the process of selecting an oncology development candidate for its Hippo signaling pathway program.

    The Company has a scientific team of approximately 80 people with deep expertise in the fields of biology, medicinal and computational chemistry, pharmacokinetics and pharmacology, and clinical development. It owns an extensive library of approximately 240,000 pharmacologically relevant molecules, approximately 60% of which are proprietary, as well as a wholly-owned research and development facility.

    Inventiva is a public company listed on compartment C of the regulated market of Euronext Paris (ticker: IVA - ISIN: FR0013233012) and on the Nasdaq Global Market in the United States (ticker: IVA). www.inventivapharma.com.

    Contacts

    Inventiva
    Pascaline Clerc
    VP of Global External Affairs
    media@inventivapharma.com

    +1 240 620 9175     		Brunswick Group
    Tristan Roquet Montegon /
    Aude Lepreux / Matthieu Benoist
    Media relations
    inventiva@brunswickgroup.com
    +33 1 53 96 83 83     		Westwicke, an ICR Company
    Patricia L. Bank
    Investor relations

    patti.bank@westwicke.com
    +1 415 513 1284

    Important Notice

    This press release contains “forward-looking statements” within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, included in this press release are forward-looking statements. These statements include, but are not limited to, forecasts and estimates with respect to Inventiva’s pre-clinical programs and clinical trials, including recruitment,  screening and enrolment for those trials, including LEGEND, clinical trial data releases and publications, the information, insights and impacts that may be gathered from clinical trials, including LEGEND, the potential therapeutic benefits of lanifibranor in combination with empagliflozin, the design of trials, including LEGEND,  pipeline and preclinical and clinical development plans, milestone payments, royalties and product sales, future activities, expectations, plans, growth and prospects of Inventiva and the sufficiency of Inventiva’s cash resources and cash runway. Certain of these statements, forecasts and estimates can be recognized by the use of words such as, without limitation, “believes”, “anticipates”, “expects”, “intends”, “plans”, “seeks”, “estimates”, “may”, “will”, “would”, “could”, “might”, “should”, “plans”, “designed”, “hopefully” and “continue” and similar expressions. Such statements are not historical facts but rather are statements of future expectations and other forward-looking statements that are based on management's beliefs. These statements reflect such views and assumptions prevailing as of the date of the statements and involve known and unknown risks and uncertainties that could cause future results, performance or future events to differ materially from those expressed or implied in such statements. Future events are difficult to predict and may depend upon factors that are beyond Inventiva's control. There can be no guarantees with respect to pipeline product candidates that the clinical trial results will be available on their anticipated timeline, that future clinical trials will be initiated as anticipated, that product candidates will receive the necessary regulatory approvals, or that any of the anticipated milestones by Inventiva or its partners will be reached on their expected timeline, or at all. Actual results may turn out to be materially different from the anticipated future results, performance or achievements expressed or implied by such statements, forecasts and estimates, due to a number of factors, including that Inventiva is a clinical-stage company with no approved products and no historical product revenues, Inventiva has incurred significant losses since inception, Inventiva has a limited operating history and has never generated any revenue from product sales, Inventiva will require additional capital to finance its operations, Inventiva's future success is dependent on the successful clinical development, regulatory approval and subsequent commercialization of current and any future product candidates, preclinical studies or earlier clinical trials are not necessarily predictive of future results and the results of Inventiva's clinical trials may not support Inventiva's product candidate claims, Inventiva may encounter substantial delays in its clinical trials or Inventiva may fail to demonstrate safety and efficacy to the satisfaction of applicable regulatory authorities, enrolment and retention of patients in clinical trials is an expensive and time-consuming process and could be made more difficult or rendered impossible by multiple factors outside Inventiva's control, Inventiva's product candidates may cause adverse drug reactions or have other properties that could delay or prevent their regulatory approval, or limit their commercial potential, Inventiva faces substantial competition and Inventiva’s business, and preclinical studies and clinical development programs and timelines, its financial condition and results of operations could be materially and adversely affected by the current COVID-19 pandemic and geopolitical events, such as the conflict between Russia and Ukraine and related impacts and potential impacts on the initiation, enrolment and completion of Inventiva’s clinical trials on anticipated timelines. Given these risks and uncertainties, no representations are made as to the accuracy or fairness of such forward-looking statements, forecasts and estimates. Furthermore, forward-looking statements, forecasts and estimates only speak as of the date of this press release. Readers are cautioned not to place undue reliance on any of these forward-looking statements.

    Please refer to the Universal Registration Document for the year ended December 31, 2021 filed with the Autorité des Marchés Financiers on March 11, 2022 and the Annual Report on Form 20-F for the year ended December 31, 2021 filed with the Securities and Exchange Commission on March 11, 2022 for additional information in relation to such factors, risks and uncertainties.

    All information in this press release is as of the date of the release. Except as required by law, Inventiva has no intention and is under no obligation to update or review the forward-looking statements referred to above.

    Attachment


Share on,